Increasing Sphingolipid Synthesis Alleviates Airway Hyperreactivity.

TitleIncreasing Sphingolipid Synthesis Alleviates Airway Hyperreactivity.
Publication TypeJournal Article
Year of Publication2020
AuthorsHeras AF, Veerappan A, Silver RB, Emala CW, Worgall TS, Perez-Zoghbi J, Worgall S
JournalAm J Respir Cell Mol Biol
Date Published2020 Jul 24

RATIONALE: Impaired sphingolipid synthesis is linked genetically to childhood asthma and functionally to airway hyperreactivity.

OBJECTIVES: To investigate if sphingolipid synthesis could be a target for asthma therapeutics.

METHODS: The effects of GlyH-101 and fenretinide via modulation of de novo sphingolipid synthesis on airway hyperreactivity was evaluated in mice deficient in serine palmitoyl-CoA transferase, the rate limiting enzyme of sphingolipid synthesis. The drugs were also used directly in human airway smooth muscle and epithelial cells to evaluate changes in de novo sphingolipid metabolites and calcium release.

RESULTS: GlyH-101 and fenretinide increased sphinganine and dihydroceramides (de novo sphingolipid metabolites) in lung epithelial and airway smooth muscle cells, decrease intracellular calcium concentration in airway smooth muscle cells, and decrease agonist-induced contraction in proximal and peripheral airways. GlyH-101 also decreased airway hyperreactivity in SPT-deficient mice in vivo.

CONCLUSIONS: This study identifies the manipulation of sphingolipid synthesis as a novel metabolic therapeutic strategy to alleviate airway hyperreactivity.

Custom 1

Alternate JournalAm. J. Respir. Cell Mol. Biol.
PubMed ID32706610
Grant ListR01 HL122340 / HL / NHLBI NIH HHS / United States

Weill Cornell Medicine Gale and Ira Drukier Institute for Children's Health 413 E. 69th Street New York, NY 10021